{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fskinandjointspodcast.simplecast.com%2Fepisodes%2Faadgooderham-AtTQxxrM","width":444,"version":"1.0","type":"rich","title":"AAD 2024 LATEBREAKER: Delgocitinib for Long-Term Use in Chronic Hand Eczema","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/68c7c404-90cd-40bb-a9b7-40fa437eb547/copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-of-copy-50.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"","height":200,"description":"🎙️ Melinda Knows Best at the AAD! 🌟\n\nWe’ve got a special LATEBREAKER episode for you, continuing our coverage from the American Academy of Dermatology in San Diego! \n\n👟💡 Pro Tip: Don't miss Dr. Gooderham’s advice on navigating massive convention centers in style and comfort!\n\n->We dive into the highly anticipated Delta 3 study, shedding light on long-term safety and efficacy of Delgocitinib cream for Chronic Hand Eczema. \n\n---->Subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.\n\n->Practical Tips for Dermatology Practices 🏥💼\nAdapting treatment plans for chronic hand eczema.\nBenefits of as-needed treatment approaches for better patient outcomes.\n\n->Dr. Gooderham’s Conference Adventures 🛫👩‍⚕️👨‍⚕️\nDr. Gooderham also shares her intriguing encounters from Toronto to San Diego, including a surprise meeting with April Armstrong and an old friend from med school. 🛫\n\nEpisode Learning Objectives:\nUnderstand the primary and secondary endpoints of the Delta 3 study and its implications for treating chronic hand eczema.\nLearn about the safety profile of Delgocitinib cream and its significance in long-term treatment plans.\nGain insights into real-world application of delgocitinib and patient adherence strategies for topical treatments\n\nLace up those sneakers, grab a protein bar, and join us for a walk through the latest dermatological advancements! 🥾🍫\n🎙️ Melinda Knows Best at the AAD – where expert insights meet real-world application (pun intended)📍📍\n\nEpisode supported by an IME Grant from LEO Pharma\n\n\n\nABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)\n\nDermatologist  | Toronto \n\nToronto, ON\n\nMelinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.\n\nDr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.\n\n\n\nReferences\n\nGooderham M. Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial. Presented at: 2024 American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA.\n\n\n\n\n\n\n\n\n\n"}